Sermorelin is a growth hormone-releasing hormone analogue, commonly identified as GHRH-(1-29)-amide. Its research history includes studies of hormone responses and selected outcomes in older adults. That makes it a legitimate subject for investigation, but it does not turn every claim about.
Tesamorelin has a specific clinical research and product history centered on excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Its evidence should be read in that setting before being applied to general belly-fat, weight-loss, or muscle-growth claims. The relevant outcome.
CJC-1295/ipamorelin is a combination label, not a single standardized intervention. The essential questions are which CJC preparation is present, how much of each ingredient is included, and whether the exact combination has been studied for the claimed outcome. Research on the ingredients.